Clinical Review Provides Tailored Management Strategies for Constipation with Bloating, Differentiating CIC and IBS-C

Constipation and bloating are highly prevalent and often co-occurring gastrointestinal (GI) symptoms that significantly impact quality of life. Current approaches frequently treat constipation, assuming bloating will resolve, but this strategy is not always effective due to the complex and often nonspecific nature of bloating's pathophysiology. There is a critical need for a more nuanced clinical approach to identify the specific underlying conditions, such as chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C), to enable personalized and more effective therapeutic interventions.

This comprehensive clinical review synthesizes current knowledge on the evaluation and management of patients experiencing both constipation and bloating. The authors screened 733 articles, ultimately including 12 studies, comprising randomized and observational trials, along with a large cohort of 18,386 participants, to inform their discussion. Key areas reviewed include potential etiologies, clinical evaluation methods, and differentiation between common underlying causes like chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Management approaches discussed encompass dietary modification, biofeedback, and a range of pharmacologic therapies, including over-the-counter treatments, plecanatide, linaclotide, lubiprostone, tenapanor, neuromodulators, and antibiotics.

Out of 733 articles screened, 12 studies met predefined inclusion criteria, including one large cohort of 18,386 participants, along with randomized and observational trials of smaller size. The review found that while specifically treating constipation may also improve bloating, this strategy does not improve bloating in all patients. It emphasizes the importance of differentiating underlying conditions like CIC and IBS-C for tailored management. Pharmacologic options discussed include secretagogues like plecanatide, linaclotide, and lubiprostone, as well as tenapanor, neuromodulators, and antibiotics.

The review highlights that bloating is a relatively nonspecific symptom with complex pathophysiology, underscoring the need for personalized medicine approaches to improve treatment outcomes. Dietary modification and biofeedback are also presented as non-pharmacologic strategies. The authors conclude that further research is needed to understand the physiology of bloating better, especially in the context of GI and non-GI symptoms.